Advances in clinical research on nephrology in 2020

doi:10.3877/cma.j.issn.2095-3216.2021.01.003

Abstract

Abstract:

This article summarized the important progress of clinical research in nephrology in 2020, mainly including primary glomerular diseases (IgA nephropathy, membranous nephropathy) and secondary glomerular diseases (diabetic nephropathy, lupus nephritis, kidney damage due to anti-neutrophil cytoplasmic antibody-associated vasculitis, blood system disease-related kidney damage), acute kidney injury, and chronic kidney disease-mineral and bone disorders. These advances will greatly help the clinical work in terms of disease diagnosis, prognosis judgment, and treatment guidance.

Key words: Clinical research, Primary glomerular disease, Secondary glomerular disease, Acute kidney injury, CKD-MBD

Chengning Zhang, Bo Zhang, Huijuan Mao, Changying Xing. Advances in clinical research on nephrology in 2020[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(01): 14-19.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.01.003

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I01/14

References 49

[1]	Faria B, Canao P, Cai Q, et al. Arteriolar C4d in IgA nephropathy: a cohort study [J]. Am J Kidney Dis, 2020, 76(5): 669-678.
[2]	Yu GZ, Guo L, Dong JF, et al. Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study [J]. Am J Kidney Dis, 2020, 76(1): 90-99.
[3]	Rehnberg J, Symreng A, Ludvigsson JF, et al. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: a Swedish population-based cohort study [J]. J Am Soc Nephrol, 2020, Epub ahead of print.
[4]	Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy [J]. Kidney Int, 2020, 98(4): 1044-1052.
[5]	Barbour SJ, Canney M, Coppo R, et al. Improving treatment decisions using personalized risk assessment from the international IgA nephropathy prediction tool [J]. Kidney Int, 2020, 98(4): 1009-1019.
[6]	Zhang J, Huang B, Liu Z, et al. External validation of the international IgA nephropathy prediction tool [J]. Clin J Am Soc Nephrol, 2020, 15(8): 1112-1120.
[7]	Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy [J]. Kidney Int, 2020, 97(1): 163-174.
[8]	Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients [J]. Kidney Int, 2020, 98(5): 1253-1264.
[9]	Xie J, Liu L, Mladkova N, et al. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis [J]. Nat Commun, 2020, 11(1): 1600.
[10]	Reinhard L, Zahner G, Menzel S, et al. Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy [J]. J Am Soc Nephrol, 2020, 31(1): 197-207.
[11]	Fernandez-Juarez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy [J]. Kidney Int, 2020, Epub ahead of print.
[12]	Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes [J]. N Engl J Med, 2020, 382(26): 2493-2503.
[13]	Cannon CP, Perkovic V, Agarwal R, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial [J]. Circulation, 2020, 141(5): 407-410.
[14]	Oshima M, Neuen BL, Jardine MJ, et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial [J]. Lancet Diabetes Endocrinol, 2020, 8(11): 903-914.
[15]	Tofte N, Lindhardt M, Adamova K, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial [J]. Lancet Diabetes Endocrinol, 2020, 8(4): 301-312.
[16]	Malvar A, Alberton V, Lococo B, et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis [J]. Kidney Int, 2020, 97(1): 156-162.
[17]	Mok CC, Ho LY, Ying SKY, et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis [J]. Ann Rheum Dis, 2020, 79(8): 1070-1076.
[18]	Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis [J]. N Engl J Med, 2020, 383(12): 1117-1128.
[19]	Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis [J]. Arthritis Rheumatol, 2020, Epub ahead of print.
[20]	Casal Moura M, Irazabal MV, Eirin A, et al. Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease [J]. J Am Soc Nephrol, 2020, 31(11): 2688-2704.
[21]	Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis [J]. N Engl J Med, 2020, 382(7): 622-631.
[22]	Charles P, Perrodeau E, Samson M, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial [J]. Ann Intern Med, 2020, 173(3): 179-187.
[23]	Yu XJ, Zhang X, Li DY, et al. Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: a large retrospective case series study from a single institute in China [J]. Nephrology (Carlton), 2020, 25(3): 202-211.
[24]	Nasr SH, Larsen CP, Sirac C, et al. Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone [J]. Kidney Int, 2020, 97(3): 589-601.
[25]	Royal V, Leung N, Troyanov S, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study [J]. Blood, 2020, 135(21): 1833-1846.
[26]	Yadav P, Sathick IJ, Leung N, et al. Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study [J]. Blood Cancer J, 2020, 10(3): 28.
[27]	Song J, Jiang F, Liu H, et al. Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis [J]. J Clin Lab Anal, 2020, 34(2): e23057.
[28]	Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial [J]. Lancet Oncol, 2020, 21(10): 1317-1330.
[29]	Ball S, Behera TR, Anwer F, et al. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials [J]. Ann Hematol, 2020, 99(6): 1265-1271.
[30]	Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis [J]. Blood, 2020, 135(18): 1531-1540.
[31]	Gabarre P, Dumas G, Dupont T, et al. Acute kidney injury in critically ill patients with COVID-19 [J]. Intensive Care Med, 2020, 46(7): 1339-1348.
[32]	Bowe B, Cai M, Xie Y, et al. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19 [J]. Clin J Am Soc Nephrol, 2020, 16(1): 14-25.
[33]	Wald R, Bagshaw SM. COVID-19-associated acute kidney injury: learning from the first wave [J]. J Am Soc Nephrol, 2020, 32(1): 4-6.
[34]	Kolhe NV, Fluck RJ, Selby NM, et al. Acute kidney injury associated with COVID-19: a retrospective cohort study [J]. PLoS Med, 2020, 17(10): e1003406.
[35]	Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19 [J]. Kidney Int, 2020, 97(5): 829-838.
[36]	中华医学会肾脏病学分会专家组. 新型冠状病毒感染合并急性肾损伤诊治专家共识[J]. 中华肾脏病杂志，2020, 36(3): 242-246.
[37]	Nadim MK, Forni LG, Mehta RL, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup [J]. Nat Rev Nephrol, 2020, 16(12): 747-764.
[38]	Brar S, Liu KD, Go AS, et al. Prospective cohort study of renin-angiotensin system blocker usage after hospitalized acute kidney injury [J]. Clin J Am Soc Nephrol, 2020, 16(1): 26-36.
[39]	Secora AM, Shin JI, Qiao Y, et al. Hyperkalemia and acute kidney injury with spironolactone use among patients with heart failure [J]. Mayo Clin Proc, 2020, 95(11): 2408-2419.
[40]	Collaborative S. Perioperative nonsteroidal anti-inflammatory drugs (NSAID) administration and acute kidney injury (AKI) in major gastrointestinal surgery: a prospective, multicenter, propensity matched cohort study [J]. Ann Surg, 2020, Epub ahead of print.
[41]	Rampersad C, Kraut E, Whitlock RH, et al. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study [J]. Am J Kidney Dis, 2020, 76(4): 471-479.
[42]	Magee DE, Hird AE, Klaassen Z, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials [J]. Ann Oncol, 2020, 31(1): 50-60.
[43]	Gutgarts V, Jain T, Zheng J, et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery [J]. Biol Blood Marrow Transplant, 2020, 26(6): 1071-1076.
[44]	Gupta S, Seethapathy H, Strohbehn IA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor t-cell (CAR-T) therapy for diffuse large B-cell lymphoma [J]. Am J Kidney Dis, 2020, 76(1): 63-71.
[45]	Lee MD, Strohbehn IA, Seethapathy HS, et al. Acute kidney injury after the CAR-T therapy tisagenlecleucel [J]. Am J Kidney Dis, 2020, Epub ahead of print.
[46]	Weisbord SD, Palevsky PM, Kaufman JS, et al. Contrast-associated acute kidney injury and serious adverse outcomes following angiography [J]. J Am Coll Cardiol, 2020, 75(11): 1311-1320.
[47]	Itano Y, Kato S, Tsuboi M, et al. A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET trial) [J]. Kidney Int Rep, 2020, 5(12): 2168-2177.
[48]	Djuric P, Dimkovic N, Schlieper G, et al. Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study [J]. Nephrol Dial Transplant, 2020, 35(1): 162-169.
[49]	Raggi P, Bellasi A, Sinha S, et al. Effects of SNF472, a novel inhibitor of hydroxyapatite crystallization in patients receiving hemodialysis-subgroup analyses of the CALIPSO trial [J]. Kidney Int Rep, 2020, 5(12): 2178-2182.

Please choose a citation manager

Content to export